Background: In our center, the combination of streptozocin (STZ) and 5-fluorouracil (5-FU) has been used as the first-line treatment in the majority of patients with pancreatic neuroendocrine tumors (pNETs) over the past few decades. The objective of the current study was to assess the efficacy, prognostic factors and safety of the combination of STZ and 5-FU. Patients and Methods: Medical records and radiological reports of 133 patients with pNETs who received the combination of STZ and 5-FU during the period 1981-2014 were retrospectively evaluated. Results: The median survival from the start of treatment was 51.9 months in the whole group. In the radiologically evaluable patients (n = 100), progression-free survival was 23 months. Complete response was reached in 3 patients (3%), partial response in 25 patients (25%), 64 patients (64%) had stable disease, and 8 patients (8%) had progressive disease. In a multivariate analysis, surgery of the primary tumor and having a G3 tumor were significant positive and negative prognostic factors of survival from the start of treatment, respectively. Having either a G3 tumor or a stage IV tumor were significant prognostic factors for a shorter progression-free survival. Chemotherapy had to be discontinued in 29 patients due to side effects, of which kidney toxicity (mainly grades 1-2) was the most frequent. Conclusion: As shown in recent reports, the combination of STZ and 5-FU is effective in the treatment of pNETs in terms of survival and radiological response and has an acceptable toxicity profile.

Keywords:
Pancreas, Neuroendocrine tumors, Streptozocin, 5-Fluorouracil, Chemotherapy
1.
Halfdanarson TR, Rubin J, Farnell MB, et al: Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008;15:409-427.
2.
Wellbourn RB, Wood SM, Polak JM, et al: Gut Hormones, ed 2. London, Churchill Livingstone, 1981, pp 547-554.
3.
Oberg K, Eriksson B: Endocrine tumors of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781.
4.
Eriksson B, Arnberg H, Lindgren PG, et al: Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103-113.
5.
Kent RB, van Heerden J, Nejland L: Non-functioning islet cell tumors. Ann Surg 1981;193:185-190.
6.
Wilder RM, Allan FN, Power MH, et al: Carcinoma of the islands of the pancreas: hyperinsulinism and hypoglycemia. JAMA 1927;89:348-355.
7.
Zollinger RM, Ellison EH: Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-728.
8.
Mallinson CN, Bloom SR, Warin AP, et al: A glucagonoma syndrome. Lancet 1974;2:1-5.
9.
Verner JV, Morrison AB: Islet cell tumor and a syndrome of refractory diarrhea and hypokalemia. Am J Med 1958;25:374-380.
10.
Fjällskog ML, Janson ET: Treatment of pancreatic NETs. Acta Oncol 2005;44:329-338.
11.
Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;20;303:1189-1194.
12.
Eriksson B, Skogseid B, Lundqvist G, et al: Medical treatment and long-term survival in a prospective study of 84 patients with pancreatic NETs. Cancer 1990;65:1883-1890.
13.
Eriksson B, Oberg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-208.
14.
Fjällskog ML, Granberg DP, Welin SL, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107.
15.
Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
16.
Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
17.
Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30:2963-2968.
18.
Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
19.
Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
20.
Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
21.
Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
22.
Chan JA, Blaszkowsky L, Stuart K, et al: A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer 2013;119:3212-3218.
23.
Bosman F, Carneiro F, Hruban RH, et al: WHO Classification of Tumors of the Digestive System. Lyon, IARC Press, 2010.
24.
Scarpa A, Mantovani W, Capelli P, et al: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-833.
25.
Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
26.
Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
27.
Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981;47:207-214.
28.
Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
29.
Hodul PJ, Strosberg JR, Kvols LK: Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 2008;15:314-321.
30.
Falconi M, Bartsch DK, Eriksson B, et al; Barcelona Consensus Conference participants: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-134
31.
Ekeblad S, Skogseid B, Dunder K, et al: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803.
32.
Pavel M, Dilz LM, Denecke T, et al: Streptozocin-based chemotherapy in patients with advanced pancreatic neuroendocrine tumors. J Clin Oncol 2014;32(suppl 3; abstr 295).
33.
Rindi G, Falconi M, Klersy C, et al: TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012;104:764-777.
34.
Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
35.
Ducreux M, Dahan L, Smith D, et al: Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - a phase II non-randomised trial. Eur J Cancer 2014;50:3098-3106.
36.
Lambertini D, Bottini E, Talassi E, et al: Acute renal failure caused by VIP-secreting tumor. G Ital Nefrol 2003;20:419-422.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.